NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan
SEOUL, South Korea, April 9, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that it has entered into an exclusive distribution agreement in Japan with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable...
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development,...
Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care. PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of...
GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era
The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by 2030. PISCATAWAY, N.J. and LOS ANGELES, April 9, 2026 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of CMOS-based DNA synthesis technologies, and Mimulus Corp, the pioneer in Molecular Archive Technology™, today announced a strategic...
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been accepted for review by the China National Medical Products Administration (NMPA). With the BLA filing, DualityBio is seeking approval for...
OncoC4 announces first participant’s dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer’s disease
ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug (IND) application for a Phase 1/2 clinical trial of ONC-841, the company's investigational Alzheimer's disease therapy by the National Medical Product Administration (NMPA). The clinical...
Kelun-Biotech Approved by HKEX to Remove “B” Marker from Stock Code, Representing a New Stage of Development
CHENGDU, China, April 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong...
Ping An Launches “Service Year 2026”: Upgrades AI‑Powered Express Service and Global Emergency Assistance
HONG KONG and SHANGHAI, April 9, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) today announced major upgrades to its AI‑powered Express Service and Global Emergency Assistance, marking the launch of its "Service Year 2026" initiative. The upgrades reflect Ping An's continued focus on strengthening customer...
Taiwan-Based Towards Buddha Co., Ltd. Showcases Medical-Grade TPU Tubing Injection Solutions at Medtec Japan 2026
TAINAN, April 9, 2026 /PRNewswire/ -- Towards Buddha Co., Ltd., a Taiwan-based manufacturer of medical-grade plastic components, will exhibit at Medtec Japan 2026 this April, presenting its integrated TPU tubing injection manufacturing solutions in collaboration with ICP DAS BMP, a supplier of high-performance medical-grade materials. Medtec Japan is one of Asia's leading exhibitions for medical device design and manufacturing, attracting global innovators and...
111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results
Continuing Transition to an Asset-Light Business Model to Improve Overall Efficiency Delivered Non-GAAP Operating Profitability in Both Q4'25 and FY'25 Generated Positive Operating Cash Flow for Both Q4'25 and FY'25 Continued Gross Profit Margin Expansion for B2B Business in Both Q4'25 and FY'25 SHANGHAI, April 9, 2026 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a...
